Neuroprotection With Statin Therapy for Acute Recovery Trial Phase 2 "NeuSTART2"


Phase 2 Results N/A

Summary of Purpose

This trial will be a phase 2 randomized safety study in which ischemic stroke patients will be randomly assigned within 24 hours of symptom onset to placebo or standard dose lovastatin versus short-term high-dose lovastatin 640 mg per day for 3 days. The primary outcome of this Phase 2 study will be musculoskeletal and hepatic toxicity, defined by clinical and laboratory criteria, with a 3-month follow-up period...

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 20 July 2017.

1 Feb 2009 30 Oct 2013 1 Jan 2017 1 Jan 2017 1 Jul 2017 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Design

  • Allocation: Randomized
  • Masking: Double Blind (Subject, Caregiver, Investigator)
  • Purpose: Treatment
  • Endpoint: Safety/Efficacy Study
  • Intervention: Parallel Assignment